Immuno-oncology
Conference Coverage
VIDEO: Immune therapy effective, durable in treatment-naive melanoma brain metastases
CHICAGO – For patients with asymptomatic brain metastases from melanoma who had not had prior treatment, nivolumab combined with ipilimumab...
Conference Coverage
VIDEO: Immunotherapy ups disease control rate in relapsed mesothelioma
CHICAGO – Early data from a phase II trial of immune checkpoint inhibitors to treat relapsed mesothelioma give hope that immunotherapy may be an...
Conference Coverage
VIDEO: Combined immunotherapy strategy shows promise in advanced solid tumors
CHICAGO – IgG1 agonist monoclonal antibody plus nivolumab induced durable partial responses in patients with tumors thought to be insensitive to...
Conference Coverage
Immune-agonist combo has activity against several tumor types
CHICAGO – How can we improve responses in heavily pretreated patients with a variety of tumor types?
News
FDA approves pembrolizumab for advanced urothelial carcinoma
Pembrolizumab is the third checkpoint inhibitor approved for bladder cancer this month.
From the Journals
Pembrolizumab shows some activity against advanced endometrial cancer
(Keytruda)
Conference Coverage
Salvage chemo for NSCLC more effective after PD-1/PD-L1 inhibitors
GENEVA – Salvage chemotherapy was more effective among patients who had disease progression following immunotherapy in the second line than among...
Conference Coverage
Atezolizumab improves OS in NSCLC with brain metastases
GENEVA – Immune checkpoint inhibitors may improve survival in patients with non–small cell lung cancer (NSCLC) and brain metastases compared with...
News
FDA approves pembrolizumab for first-line advanced NSCLC
The approval was based on an improved overall response rate and progression-free survival in a cohort of 123 patients.
Conference Coverage
SLE linked to subsequent risk of malignant melanoma
PORTLAND, ORE. – An analysis of electronic medical records has identified another malignancy associated with systemic lupus erythematosus.
Conference Coverage
Flu shots may spark immune adverse events in PD-1 blockade for NSCLC
GENEVA – More than half of patients who had received a trivalent influenza vaccine in a small study had immune-related adverse events.